key: cord-0700260-wrzmgnrb
authors: Sjoding, Michael W.; Admon, Andrew J.; Saha, Anjan K.; Kay, Stephen G.; Brown, Christopher A.; Co, Ivan; Claar, Dru; McSparron, Jakob I.; Dickson, Robert P.
title: Comparing Clinical Features and Outcomes in Mechanically Ventilated Patients with COVID-19 and Acute Respiratory Distress Syndrome
date: 2021-03-30
journal: Annals of the American Thoracic Society
DOI: 10.1513/annalsats.202008-1076oc
sha: afa88e2dbd25c75214cc554d2e819ee94a140098
doc_id: 700260
cord_uid: wrzmgnrb

Rationale: Patients with severe coronavirus disease (COVID-19) meet clinical criteria for the acute respiratory distress syndrome (ARDS), yet early reports suggested they differ physiologically and clinically from patients with non–COVID-19 ARDS, prompting treatment recommendations that deviate from standard evidence-based practices for ARDS. Objectives: To compare respiratory physiology, clinical outcomes, and extrapulmonary clinical features of severe COVID-19 with non–COVID-19 ARDS. Methods: We performed a retrospective cohort study, comparing 130 consecutive mechanically ventilated patients with severe COVID-19 with 382 consecutive mechanically ventilated patients with non–COVID-19 ARDS. Initial respiratory physiology and 28-day outcomes were compared. Extrapulmonary manifestations (inflammation, extrapulmonary organ injury, and coagulation) were compared in an exploratory analysis. Results: Comparison of patients with COVID-19 and non–COVID-19 ARDS suggested small differences in respiratory compliance, ventilatory efficiency, and oxygenation. The 28-day mortality was 30% in patients with COVID-19 and 38% in patients with non–COVID-19 ARDS. In adjusted analysis, point estimates of differences in time to breathing unassisted at 28 days (adjusted subdistributional hazards ratio, 0.98 [95% confidence interval (CI), 0.77–1.26]) and 28-day mortality (risk ratio, 1.01 [95% CI, 0.72–1.42]) were small for COVID-19 versus non–COVID-19 ARDS, although the confidence intervals for these estimates include moderate differences. Patients with COVID-19 had lower neutrophil counts but did not differ in lymphocyte count or other measures of systemic inflammation. Conclusions: In this single-center cohort, we found no evidence for large differences between COVID-19 and non–COVID-19 ARDS. Many key clinical features of severe COVID-19 were similar to those of non–COVID-19 ARDS, including respiratory physiology and clinical outcomes, although our sample size precludes definitive conclusions. Further studies are needed to define COVID-19–specific pathophysiology before a deviation from evidence-based treatment practices can be recommended.

Coronavirus disease (COVID-19) causes hypoxic respiratory failure via severe lung injury. Most patients with severe COVID-19 meet clinical criteria for acute respiratory distress syndrome (ARDS), defined by hypoxemia and bilateral opacities on chest radiographs without evidence of left-sided cardiac dysfunction (1) . Yet early reports suggested that the respiratory physiology among patients with severe COVID-19 might differ from that of non-COVID-19 ARDS, reflecting distinct pathophysiology, and thus should be managed differently (2, 3) . In addition, early reports suggested greater mortality among mechanically ventilated patients with COVID-19 than historic ARDS cohorts (4) (5) (6) . The question of whether severe COVID-19 represents "atypical ARDS" or even non-ARDS pathophysiology has been a major source of controversy (7) (8) (9) .

In addition, numerous extrapulmonary clinical features have been identified as abnormal in COVID-19, which prompted widespread variation in routine intensive care unit (ICU) management. Patients with COVID-19 have been described as hyperinflammatory, exhibiting a "cytokine storm," prompting empiric and unproven use of potent, targeted immune modulators (e.g., interleukin-6 inhibition via monoclonal antibodies) (10, 11) . Patients with COVID- 19 have been described as hypercoagulable, with disordered indices of coagulation, prompting widespread escalation of routine ICU anticoagulation practices, even including empiric administration of thrombolytic therapy (12, 13) . Finally, mechanically ventilated patients with COVID-19 develop high rates of extrapulmonary organ injury, prompting suggestions that conventional ARDS ventilator strategies may compromise patient hemodynamics and perpetuate multiorgan failure (3, 9, 14, 15) . Some authors have even recommended deviating from standard ARDS evidence-based management strategies in severe COVID-19 (3, 9, 16) , although others have strongly cautioned against such strategies (17, 18) .

Yet these clinical features-variable respiratory mechanics, hyperinflammation, hypercoagulability, and extrapulmonary organ injury-are common among critically ill patients without COVID-19, including patients with ARDS. No study to date has systematically compared all of these clinical features of COVID-19 with a cohortof patients with non-COVID-19 ARDS; the diseasespecific pathophysiologic features of severe COVID-19 have yet to be elucidated. We performed a retrospective cohort study comparing patients with COVID-19 who received invasive mechanical ventilation with historical control subjects with ARDS from the same tertiary care center, hypothesizing that there would be no large differences between groups in these key clinical features.

We performed a single-center retrospective cohort study. We studied consecutive adult patients (age >18 yr) with COVID-19 requiring invasive mechanical ventilation who were admitted between March 1 and June 31, 2020. All patients were observed 28 days after the onset of invasive mechanical ventilation. A CONSORT diagram is provided in Figure E1 in the online supplement. COVID-19 was diagnosed using real-time reverse transcriptase-polymerase chain reaction for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We excluded patients who were transferred for extracorporeal membrane oxygenation or initiated on invasive ventilation before the date of transfer. We excluded patients who lacked documentation in the electronic medical record of 1) height and weight, 2) arterial oxygen pressure (Pa O 2 )/fraction of inspired oxygen (FI O 2 ) ratio (or arterial oxygen saturation [Sa O 2 ]/FI O 2 ratio [19] if no arterial blood gas was obtained), or 3) static lung compliance measurement (all within the first 24 h of invasive mechanical ventilation).

We compared patients with COVID-19 with consecutive adult patients with ARDS not caused by COVID-19 admitted between January 1, 2016, and December 31, 2017, at the same center. Portions of this cohort have been described in previous studies (20, 21) . ARDS was determined using formal post hoc adjudication by critical care-trained physicians using the Berlin Criteria as previously described (20) . The additional inclusion and exclusion criteria were the same as the COVID-19 cohort.

We collected baseline demographic data, including age, sex, self-reported race, height, and weight for all patients. Median values of Pa O 2 /FI O 2 ratio (or Sa O 2 /FI O 2 ratio), oxygenation index (or oxygen saturation index if no arterial blood gas was obtained [22] ), and ventilatory ratio (23) were calculated from the electronic health record during the first 24 hours of mechanical ventilation. All values of static lung compliance measured at the same positive end-expiratory pressure (PEEP) were also collected during the first 24 hours and the median value was determined. The highest sequential organ failure assessment (SOFA) score over the first 24 hours of mechanical ventilation was determined. We also extracted laboratory values from the electronic health record closest to the initiation of invasive mechanical ventilation, all within 48 hours of intubation. Analyses were not adjusted for multiplicity and thus should be considered exploratory.

We compared lung compliance, ventilatory ratio, and oxygenation index before and after matching patients based on age, sex, body mass index (BMI), and the initial PEEP. Patients were matched on these characteristics because they may have an effect on respiratory mechanics independent of ARDS or COVID-19. We performed coarsened exact matching to compare these physiologic parameters in a 1:1 matched subgroup. Coarsened exact matching is a commonly used matching approach in which exact matching is performed after first "coarsening" the data (24, 25) . For example, BMI is first coarsened into meaningful subgroups based on user-defined cut points or a default binning method, and then exact matches are made within subgroups. Additional matching details are described in the online supplement and matching results are shown in Table E1 . We compared median physiologic variables in the unmatched and matched cohorts and performed quantile regression to estimate 95% confidence intervals (CIs) of differences in medians.

We compared time to breathing unassisted from mechanical ventilation before 28 days, which is measured from the first to the last time the patient received invasive mechanical ventilation during the hospitalization. We plotted a time-to-event curve for the time to breathing unassisted from mechanical ventilation before 28 days. To account for the competing risk of death, patients who died before Day 28 were assigned more than 28 days of invasive mechanical ventilation. We also determined patient status at 28 days, which included death, still hospitalized receiving ORIGINAL RESEARCH invasive mechanical ventilation, hospitalized but breathing unassisted, and discharged. Because our institution collects death data after discharge for some patients, if there was a record that the patient died within 28 days of invasive mechanical ventilation, but after discharge, they were included as a death.

To compare time to breathing unassisted in an adjusted analysis, we fit a competing risk survival model with death as competing risk and reported the subdistributional hazards ratio (SHR). We adjusted for age, sex, selfreported race, BMI, and maximum SOFA score during the first 24 hours of mechanical ventilation. We did not adjust for measures of severity of gas exchange (e.g., oxygenation index) as these may be in the causal pathway between COVID-19 or ARDS and death. To compare 28-day mortality, we fit a log binomial model adjusting for the same covariates. To estimate adjusted mortality rates, we calculated the average marginal effect in each group after fitting the model.

Certain laboratory tests were routinely obtained in all patients with COVID-19 but not among patients with non-COVID-19 ARDS, for whom specific laboratory testing was performed based on provider discretion. This resulted in differences in missingness between groups. Median differences in laboratory results were compared in patients who had the test performed. In an additional analysis described in the online supplement, laboratory results were compared after multiple imputations (26) . The missingness rates and variables used in multiple imputations are described in Table E5 .

As an additional sensitivity analysis, physiologic characteristics and outcomes among patients with COVID-19 were also compared with patients with non-COVID-19 ARDS and pneumonia (as adjudicated by reviewing physicians). All statistical analysis was performed in Stata version 16.1 (STATA). The institutional review board of the University of Michigan Healthcare System (HUM00104714) approved the human study protocol and deemed that informed consent was not required.

We identified 130 consecutive patients with COVID-19 who received invasive mechanical ventilation and 382 historical patients with non-COVID-19 ARDS who met all study inclusion criteria ( Figure E1 ). The baseline characteristics of both groups are shown in Table 1 . Of the mechanically ventilated patients with COVID-19, 123/130 (95%) met Berlin Criteria for ARDS as adjudicated post hoc. There were differences in patient age, sex, self-reported race, and BMI between groups. The median delivered tidal volume was 5.9 ml/ kg predicted body weight (interquartile range [IQR], 5.2-6.9) in COVID-19 and 6.0 ml/kg predicted body weight (IQR, 5.4-6.8) in non-COVID-19 ARDS, whereas median delivered PEEP was 12 (IQR, 8, 14) and 8 (IQR, 5,12) for COVID-19 and non-COVID-19 ARDS, respectively. There were 182/382 (47.6%) patients with non-COVID ARDS and 66/130 (50.7%) patients with COVID-19 who had a Pa O 2 /FI O 2 ratio , 100 at any point during invasive mechanical ventilation. There were 33/130 (25%) patients with COVID-19 and 9/ 382 (2%) patients with non-COVID-19 ARDS who received prone positioning during the hospitalization.

First, we compared respiratory physiology at the onset of invasive mechanical ventilation in patients with COVID-19 and non-COVID-19 ARDS (see Figure 1A and Table E2 ). Respiratory compliance was low in both cohorts, with only 13.1% of patients with COVID-19 and 10.5% of patients with non-COVID-19 ARDS having respiratory compliance greater than 50 ml/cm H 2 O, and only 3.1% of patients with COVID-19 and 3.4% of patients with non-COVID-19 ARDS having respiratory compliance equal to or greater than 70 ml/cm H 2 O (normal respiratory compliance in mechanically ventilated patients without a respiratory disease [27, 28] We next compared 28-day clinical outcomes among patients with COVID-19 and non-COVID-19 ARDS (Figure 2 . When the analysis was limited to patients with non-COVID-19 ARDS and pneumonia as an identified risk factor, initial pulmonary physiology was similar although ventilator-free days were higher in pneumonia causing ARDS compared with COVID-19 (Table E3) .

We performed an exploratory analysis to identify potential differences in systemic inflammation, extrapulmonary organ injury, and disordered coagulation among patients 

with COVID-19 and patients with non-COVID-19 ARDS with laboratory results performed ( Figure 3 and . Elevated D-dimer concentrations were common in both cohorts when measured, and higher among patients with non-COVID-19 ARDS (4.9 mg/L [IQR, 2-12.5] versus 2.0 mg/ L [IQR, 1.1-6.9]), although there were many missing D-dimer measurements among patients with ARDS (79%, 81/382). The analysis comparing laboratory results with missing data imputed using multiple imputations was largely similar (Table E5 ).

We compared a moderate-sized series of patients with COVID-19 who received invasive mechanical ventilation with patients with non-COVID-19 ARDS who also received invasive mechanical ventilation at the same center. We did not identify major differences between the two groups in their respiratory physiology or 28-day clinical outcomes.

Early anecdotal reports suggested that most patients with severe COVID-19 exhibit "atypical ARDS" with "near-normal respiratory system compliance," reflecting unique, non-ARDS pathophysiology (2, 3, 9, 16 ). Yet our findings that patients with COVID-19 have profoundly impaired respiratory mechanics, comparable to those of patients with non-COVID-19 ARDS, are aligned with numerous cohort studies now representing over 1,800 mechanically ventilated patients with COVID-19 across medical centers and continents (8, (30) (31) (32) (33) (34) (35) (36) (37) (38) (39) (40) . Our results also validate several recent studies that directly compared respiratory mechanics in cohorts of patients with COVID-19 and non-COVID-19 ARDS and found no meaningful difference in respiratory system compliance or other indices of respiratory mechanics (33, 38, 39) . A recently published series of 32 patients with COVID-19, which reported preserved respiratory compliance in COVID-19 compared with non-COVID-19 ARDS, was an outlier among this group (41) . The findings of our single-center study should be interpreted in the context of this now ARDS. When plotting the time-to-event curve, outcomes were censored at 28 days and patients who died before 28 days were assigned 28 days of mechanical ventilation to account for death as a competing risk. The unadjusted subdistributional HR for time to breathing unassisted was calculated using a competing risk survival model, which also accounts for death as a competing risk. ARDS = acute respiratory distress syndrome; CI = confidence interval; HR = hazard ratio.

considerable literature (e.g., in a systematic meta-analysis).

Although both of our cohorts (COVID-19 and non-COVID-19 ARDS) had considerable physiologic heterogeneity, very few patients in either cohort had "near-normal" respiratory compliance (27, 28) . In fact, the respiratory compliance of our COVID-19 cohort (34.6 ml/H 2 O) was nearly identical to that of the 4,188-patient cohort used to derive and validate the Berlin Definition of ARDS (34.0 ml/H 2 O) (1) or that of recent clinical trials of patients with severe ARDS (e.g., the PROSEVA trial, 35 ml/H 2 O [42] ). Although authors have conjectured that impaired respiratory compliance is a temporally late feature of COVID-19 lung injury, with patients initially presenting with preserved compliance (3, 9, 16) , four studies comprising over 600 mechanically ventilated patients with COVID-19 have reported serial measurements of respiratory compliance (8, (34) (35) (36) , none finding any temporal trend toward decreased compliance after initiation of mechanical ventilation. A recent metaanalysis of three studies also found no correlation between duration of symptoms and respiratory compliance in patients with COVID-19 (33, 43) . Although our confidence intervals exclude large differences in physiologic measurements across COVID-19 and non-COVID-19 ARDS cohorts, the range of possible differences supported by our compliance data could correspond to a 2-4% difference in predicted mortality based on recent work in ARDS cohorts (44) . Taken together, our study and other large series do not support the claim that patients with COVID-19 exhibit unique or atypical respiratory mechanics compared with other causes of ARDS.

The 28-day mortality rate of 30% among our COVID-19 cohort contrasts starkly with initial reports describing very high mortality among mechanically ventilated patients with COVID-19 (88-97%) (4, 45) . This discrepancy is at least partly explained by the administrative censoring used in early studies, in which only patients with an outcome of death or discharge were analyzed at the time of study reporting, excluding many other patients still hospitalized. In contrast, we restricted our analysis to patients with COVID-19 who were observed at least 28 days after the onset of invasive mechanical ventilation. Both our clinical outcomes and our ventilator management (assessed in terms 

of lung-protective ventilation and PEEP strategies) were comparable to those of patients with non-COVID-19 ARDS, similar to reports at other centers. These data do not support the widespread speculation that conventional, evidence-based ventilator strategies for ARDS may cause harm in COVID-19 due to the purportedly unique pathophysiology of the disease (3, 14, 15) .

We observed considerable heterogeneity among patients with COVID-19, both in their respiratory physiology and in their extrapulmonary disease manifestations. The heterogeneity of respiratory physiology (in 

terms of both severity of lung injury and respiratory mechanics) was comparable to that of patients with non-COVID-19 ARDS, a surprising finding given that whereas COVID-19 is a pathogen-mediated disease, ARDS is a syndrome arising from highly divergent underlying etiologies. Given the welldescribed heterogeneity of ARDS, there have been multiple recent efforts to identify more uniform ARDS subgroups, such as by etiology (46) , chest imaging findings (47) , and blood biomarkers reflecting hyperinflammatory or hypoinflammatory subphenotypes (48) (49) (50) . Two recent reports have confirmed the presence of subphenotypes among critically ill patients with COVID-19 that parallel those observed in non-COVID-19 ARDS (51) and sepsis (52) . The observation that patients with severe COVID-19 still exhibit considerable heterogeneity suggests that clustering patients with ARDS by etiology (e.g., COVID-19) may not, by itself, be a sufficient strategy for identifying homogenous subgroups. Other underlying sources of biologic variation (e.g., genetic (53, 54) , metabolomic (55, 56) , and microbiologic (57-59) variation across patients) should be explored to identify clinically, prognostically, and therapeutically distinct subgroups. Our study found that many extrapulmonary clinical features of severe COVID-19 are common among patients with non-COVID-19 causes of ARDS. Although early reports identified features purportedly specific to SARS-CoV-2 pathogenesis, these studies only compared patients with COVID-19 to reference ranges derived from healthy subjects. As an example, early reports noted immune dysfunction in severe COVID-19, manifesting with lymphopenia (60) and reflecting a supposed "cytokine storm." (10) Yet our study found similar frequency and severity of lymphopenia and nonspecific indices of systemic inflammation in patients with COVID-19 and non-COVID-19 ARDS. Systemic concentrations of inflammatory cytokines are actually lower in COVID-19 than in other causes of ARDS (11, 61) , and the clinical efficacy of cytokine inhibition in COVID-19 patients has been conflicting (62) (63) (64) (65) (66) (67) . Taken together, these data underscore the critical importance of rigorously testing early pathophysiologic hypotheses before modifying clinical practice.

Similarly, early speculation blamed inappropriate mechanical ventilation, rather than SARS-CoV-2 infection, for the high rates of extrapulmonary organ injury observed in patients with severe COVID-19 (3, 14, 15, 68) . Yet our data suggest that extrapulmonary organ injury both is common among patients with COVID-19 at the time of intubation and may be comparable in frequency to that of non-COVID-19 ARDS. Although our data suggest that the pattern of discorded coagulation may be distinct among patients with COVID-19 (with higher platelet and fibrinogen values than non-COVID-19 ARDS patients), elevated D-dimer concentrations (which have been used in patients with COVID-19 to justify an escalation of anticoagulation regimens and even empiric thrombolysis [12, 13] ) are extremely common when tested in patients with non-COVID-19 ARDS. Although we are confident that COVID-19-specific features of pathogenesis will be identified, our study underscores the importance of basing inferences on adequately powered cohorts with appropriate control arms, as opposed to underpowered, uncontrolled, and anecdotal experience (7) . We emphasize that our single-center study should be interpreted in the context of the now considerable published literature of mechanically ventilated patients with COVID-19 (e.g., via meta-analysis or systematic review). Specifically, the high percentage of missing data in our comparison of coagulation parameters is an important source of bias, and these comparisons are no more than exploratory.

The current study has several limitations. Because patients were analyzed at a single center, they were all treated under largely standardized institutional practices, which may strengthen the between-group comparisons. However, the non-COVID-19 ARDS cohort was managed during a different time period than the COVID-19 cohort; thus, some important variation in clinical practice was observed (e.g., use of prone positioning). In addition, the racial demographics of our COVID-19 and non-COVID-19 ARDS cohorts differed, attributable to a high number of emergency department-to-emergency department transfers from a nearby urban center during the COVID-19 surge. Although the study's single-center nature may also limit generalizability, both the respiratory physiology and clinical outcomes of our COVID-19 cohort were similar to those of other recent well-powered COVID-19 cohorts (8, (30) (31) (32) (33) (34) (35) (36) (37) (38) (39) (40) , suggesting it is likely representative of patients with severe COVID-19. We analyzed data recorded in the electronic medical record, which introduces variation in availability and reliability of recorded measurements and precludes analysis of respiratory parameters not routinely recorded. Other practice changes during the COVID-19 surge at our institution also prevented reliable comparison of venous thromboembolic events between groups. Although our patients without COVID-19 were studied over a 2-year period, our patients with COVID-19 were studied over a single 4-month period, introducing a potential influence of seasonality. Comparison of some extrapulmonary features of disease was limited by missing laboratory values for many patients without COVID-19. Although these comparisons were robust to multiple imputations, we emphasize that this analysis is exploratory and may be confounded by other factors in clinician ordering practices.

Within the limits of our sample size, we identified only small differences in respiratory physiology between patients with COVID-19 and non-COVID-19 ARDS. Clinical outcomes were also similar between groups, although the smaller sample size of this analysis precludes more definitive conclusions.

Many key clinical features of COVID-19 (hyperinflammation, hypercoagulability, and extrapulmonary organ injury) are also common in non-COVID-19 ARDS. Although disease-specific features of SARS-CoV-2 pathogenesis will surely be elicited, we found no physiologic evidence that lung injury from COVID-19 falls outside of the heterogenous spectrum of ARDS arising from other etiologies. Further studies are needed to define COVID-19-specific clinical features before deviation from evidence-based treatment practices can be recommended.

Author disclosures are available with the text of this article at www.atsjournals.org.

ARDS Definition Task Force. Acute respiratory distress syndrome: the Berlin Definition

COVID-19 does not lead to a "typical" acute respiratory distress syndrome

Management of COVID-19 respiratory distress

the Northwell COVID-19 Research Consortium. Presenting characteristics, comorbidities, and outcomes among 5,700 patients hospitalized with COVID-19 in the New York city area

Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington state

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

The perils of premature phenotyping in COVID-19: a call for caution

Respiratory pathophysiology of mechanically ventilated patients with COVID-19: a cohort study

COVID-19 pneumonia: ARDS or not?

UK. COVID-19: consider cytokine storm syndromes and immunosuppression

Is a "cytokine storm" relevant to COVID-19?

COVID-19 critical illness pathophysiology driven by diffuse pulmonary thrombi and pulmonary endothelial dysfunction responsive to thrombolysis

Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia

Why ventilators may not be working as well for COVID-19 patients as doctors hoped

Some doctors moving away from ventilators for virus patients

COVID-19 pneumonia: different respiratory treatments for different phenotypes?

COVID-19-associated acute respiratory distress syndrome: is a different approach to management warranted?

In defense of evidence-based medicine for the treatment of COVID-19 acute respiratory distress syndrome

NIH/NHLBI PETAL Network Collaborators. Nonlinear imputation of Pa o 2 / Fi o2 from Sp o2 /Fi o2 among patients with acute respiratory distress syndrome

Interobserver reliability of the Berlin ARDS definition and strategies to improve the reliability of ARDS Diagnosis

Differences between patients in whom physicians agree and disagree about the diagnosis of acute respiratory distress syndrome

Oxygenation saturation index predicts clinical outcomes in ARDS

Ventilatory ratio: a simple bedside measure of ventilation

cem: coarsened exact matching in Stata

Causal inference without balance checking: coarsened exact matching

Multiple imputation of missing values

Pulmonary mechanics during general anaesthesia. The influence of mechanical irritation on the airway

Total respiratory compliance in anaesthetized subjects and modifications produced by noxious stimuli

Physiologic analysis and clinical performance of the ventilatory ratio in acute respiratory distress syndrome

Emory COVID-19 Quality and Clinical Research Collaborative. ICU and ventilator mortality among critically ill adults with coronavirus disease 2019

Subphenotyping acute respiratory distress syndrome in patients with COVID-19: consequences for ventilator management

Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study

Respiratory mechanics of COVID-19-versus non-COVID-19-associated acute respiratory distress syndrome

Respiratory mechanics and gas exchange in COVID-19-associated respiratory failure

Covid-19 in critically ill patients in the Seattle region -case series

COVID-19 Spanish ICU Network. Clinical features, ventilatory management, and outcome of ARDS caused by COVID-19 are similar to other causes of ARDS

Baseline characteristics and outcomes of patients with COVID-19 admitted to intensive care units in Vancouver, Canada: a case series

Pathophysiology of COVID-19-associated acute respiratory distress syndrome: a multicentre prospective observational study

COVID-19-versus non-COVID-19-related acute respiratory distress syndrome: differences and similarities

Covid Clinic Critical Care Group. SARS-CoV-2-induced acute respiratory distress syndrome: pulmonary mechanics and gas-exchange abnormalities

Physiological and quantitative CT-scan characterization of COVID-19 and typical ARDS: a matched cohort study

PROSEVA Study Group. Prone positioning in severe acute respiratory distress syndrome

COVID-19 conundrum: clinical phenotyping based on pathophysiology as a promising approach to guide therapy in a novel illness" and "Strengthening the foundation of the house of CARDS by phenotyping on the fly" and "COVID-19 phenotypes: leading or misleading

Validating measures of disease severity in acute respiratory distress syndrome

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Distinct molecular phenotypes of direct vs indirect ARDS in singlecenter and multicenter studies

AZUREA Network. Personalised mechanical ventilation tailored to lung morphology versus low positive end-expiratory pressure for patients with acute respiratory distress syndrome in France (the LIVE study): a multicentre, single-blind, randomised controlled trial

Subphenotypes in acute respiratory distress syndrome: latent class analysis of data from two randomised controlled trials

Stability of ARDS subphenotypes over time in two randomised controlled trials

Understanding heterogeneity in biologic phenotypes of acute respiratory distress syndrome by leukocyte expression profiles

Prevalence of phenotypes of acute respiratory distress syndrome in critically ill patients with COVID-19: a prospective observational study

Novel temperature trajectory subphenotypes in COVID-19

Genome-wide association study in African Americans with acute respiratory distress syndrome identifies the selectin P ligand gene as a risk factor

Genetic variation in MAP3K1 associates with ventilator-free days in acute respiratory distress syndrome

Untargeted LC-MS metabolomics of bronchoalveolar lavage fluid differentiates acute respiratory distress syndrome from health

Profiling of ARDS pulmonary edema fluid identifies a metabolically distinct subset

Biomarker Analysis in Septic ICU Patients (BASIC) Consortium. Lung microbiota predict clinical outcomes in critically ill patients

Lung and gut microbiota are altered by hyperoxia and contribute to oxygen-induced lung injury

Enrichment of the lung microbiome with gut bacteria in sepsis and the acute respiratory distress syndrome

Clinical characteristics and imaging manifestations of the 2019 novel coronavirus disease (COVID-19):a multi-center study in Wenzhou city

Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes

Tocilizumab in patients hospitalized with covid-19 pneumonia

Interleukin-6 receptor antagonists in critically ill patients with Covid-19 -preliminary report

RCT-TCZ-COVID-19 Study Group. Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia: a randomized clinical trial

BACC Bay Tocilizumab Trial Investigators. Efficacy of tocilizumab in patients hospitalized with Covid-19

Tocilizumab in hospitalized patients with COVID-19 pneumonia

Coalition covid-19 Brazil VI Investigators. Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial

Mechanical ventilation during the coronavirus disease 2019 pandemic: combating the tsunami of misinformation from mainstream and social media

Acknowledgment: The authors thank Ann Wolski, Eric Wilson, and Ryan Townshend for their assistance with data extraction from the electronic medical record. They also thank Chris Gillies, Sardar Ansari, Jonathan Motyka, and the Michigan Center for Integrative Research in Critical Care for data infrastructure and bioinformatic resources.